BRVE ▲ +5.2% - Braveheart Bio, Inc.
$BRVE - Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
06-NOV-2026 03:15 PM ET
Share this post
More filings for $BRVE
BRVE - Braveheart Bio, Inc. - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026BRVE ▼ -6.1% - Braveheart Bio, Inc.Oct 30, 2026BRVE ▼ -6.1% - Braveheart Bio, Inc.Oct 30, 2026BRVE ▲ +2.5% - Braveheart Bio, Inc.Sep 16, 2026BRVE ▲ +10.0% - Braveheart Bio, Inc.Sep 8, 2026BRVE ▲ +3.8% - Braveheart Bio, Inc.Sep 1, 2026
View full $BRVE filing history →💬 Comments
Loading comments…
Leave a comment